Bio Path reported $-488K in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Baxter International USD -214.2M 415.4M Dec/2025
Bio Path USD -488K 4.07M Sep/2025
Cipla INR 9.77B 6.21B Dec/2025
Clal Biotechnology ILS -5.44M 3.76M Dec/2022
Compugen USD 56.04M 63.94M Dec/2025
CSL USD 2.64B 116M Dec/2025
Grifols EUR 320.55M 91.01M Dec/2025
Karyopharm Therapeutics USD -17.84M 8.44M Dec/2025